Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients

A Phase 3, prospective, randomized, double-blind, multicenter trial enrolled 44 patients with severe alopecia areata to compare low-dose IL-2 against placebo. The primary efficacy endpoint was the SALT score, a measure of scalp hair loss. No results from this Phase 3 trial—including efficacy data, effect sizes, p-values, or confidence intervals—are reported in the provided information. The study follow-up duration is also not reported.

Safety and tolerability data from this trial are not reported. There is no information on adverse events, serious adverse events, or treatment discontinuations. The trial's lead sponsor was the Centre Hospitalier Universitaire de Nice.

Key limitations include the absence of reported trial results, which prevents any assessment of efficacy or safety. The sample size of 44 patients may limit the generalizability of findings once they are published. The provided context references a prior pilot study where 4 out of 5 patients showed long-lasting regrowth, but this does not constitute evidence from the Phase 3 trial itself.

In practice, low-dose IL-2 remains an investigational therapy for severe alopecia areata. Clinicians should await peer-reviewed publication of the Phase 3 results, including detailed efficacy and safety profiles, before considering any clinical implications. The current evidence base is insufficient to support treatment recommendations.

Researchers conducted a Phase 3 clinical trial to test a potential treatment for severe alopecia areata, a condition that causes patchy hair loss. The study involved 44 patients across multiple medical centers. They compared low doses of a medication called IL-2 against a placebo to see which was better at promoting long-term hair regrowth, measured by a score called SALT.

This was a major, late-stage trial designed to provide clear answers. However, the specific results from this study—like how many patients saw hair regrowth or how well the treatment worked compared to the placebo—are not yet available. The study was randomized and double-blind, which are strong methods to ensure fair testing.

Because this was a Phase 3 trial, its findings are important for determining if this treatment could become a widely available option. However, with no results reported, we cannot draw any conclusions about its effectiveness or safety. Readers should know that a treatment is not proven until final results from such a trial are published and reviewed.